Skin involvement in systemic sclerosis: rituximab

Skin involvement in systemic sclerosis: rituximab – Evidence Summary (ES7)
Information type: Evidence summaries
Source: National Institute for Health and Care Excellence
Specialities: Skin disorders
Summary
This evidence summary includes data from 7 studies that investigated rituximab (usually 375 mg/m2 weekly for 4 weeks at 0 and 6 months, or 1,000 mg at 0 and 2 weeks) for treating skin involvement in systemic sclerosis (mainly diffuse).
UKMi comment
Rituximab is not licensed for treating systemic sclerosis (or localised scleroderma) and use for this indication is off‑label.
Related links:

Skin involvement in systemic sclerosis: rituximab – Evidence Summary (ES7)